

Applicants: Jeffrey Lynn Haddox, Roswell Robert Pfister,
James Edwin Blalock, and Matteo Villain
Serial No.: To be assigned
Filed: Herewith
Page 4

Request to Transfer Sequence Listing Pursuant to 37 C.F.R. §1.821(e)

Pursuant to 37 C.F.R. §1.821(e), applicants hereby request that the Sequence Listing (both paper copy and computer-readable form) submitted in connection with U.S. Application No. 09/521,365 be transferred to the subject application. The subject application is a Rule 1.53(b) continuation of U.S. Application No. 09/521,365, filed March 8, 2000. A paper copy of the Sequence Listing is filed herewith as Exhibit A.


The undersigned hereby certifies that the sequences set forth in the subject application are identical to the sequences set forth in the Sequence Listing from U.S. Application No. 09/521,365, and that the transfer of the Sequence Listing does not involve new matter. The undersigned further certifies that the computer-readable form filed in connection with U.S. Application No. 09/521,365 is identical to the written Sequence Listing submitted in connection with U.S. Application No. 09/521,365. Additionally, the specification of the subject application has been amended to contain the correct sequence identifiers, as required by the Sequence Rules. Accordingly, transfer of the Sequence Listing is respectfully requested.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN
Attorneys for Applicants
90 Park Avenue
New York, New York 10016

(212) 697-5985

By:


Craig J. Arnold

Reg. No. 34,287

Dated: September 28, 2001
New York, NY

SCHEDULE AREDLINED VERSIONIn the Specification:

Please replace the paragraph at page 1, line 7 as follows:

Cross-reference to Related Application

This patent application is a continuation of co-pending U.S. Application No. 09/521,365, filed March 8, 2000, and entitled "SYNTHETIC COMPLEMENTARY PEPTIDES AND OPHTHALMOLOGIC USES THEREOF", the contents of which are incorporated herein by reference in their entirety, which claims benefit of provisional patent application U.S. Serial number 60/123,409, filed March 9, 1999.

Please replace the paragraph at page 4, line 7 as follows:

The present invention demonstrates an application of the molecular recognition theory, which is the generation of therapeutic agents that may be used to treat disease. Using this approach, a series of complementary peptides for the pro-gly-pro (SEQ ID NO:1) sequence were designed, synthesized, and tested as antagonists of the PMN chemoattractant, N-acetyl-PGP.

Please replace the paragraph at page 9, line 7 as follows:

The neutrophil chemoattractant, N-acetyl-PGP, plays a major role in the initiation of polymorphonuclear leukocyte (PMN) invasion into the alkali-injured eye. In the current study, sense-antisense methodology was used to develop complementary peptides as potential inhibitors of N-acetyl-PGP. The polarization assay was used to measure the potential chemotactic response of polymorphonuclear leukocytes to

synthetic N-acetyl-PGP, the ultrafiltered tripeptide chemoattractants obtained from alkali-degraded rabbit corneas, or leukotriene B₄. Inhibition was expressed as the peptide concentration required to produce 50% inhibition (ID₅₀) of polarization. Five complementary peptides were tested as potential inhibitors of N-acetyl-PGP: RTR (SEQ ID NO:2), RTRGG (SEQ ID NO:3), RTR dimer, RTR tetramer, and ASA (SEQ ID NO:4) tetramer. In addition, the RTR tetramer and both monomeric peptides (RTR and RTRGG) were tested, separately, for inhibition of the ultrafiltered tripeptide chemoattractants or LTB₄.